REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva to Participate in the UBS Global Healthcare Conference

31 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

08 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

02 окт 2024 05:30:00 Источник Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

26 сен 2024 05:30:00 Источник Nasdaq GlobeNewswire

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

09 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

27 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

21 авг 2024 03:00:00 Источник Nasdaq GlobeNewswire

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

06 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

09 июл 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

29 май 2024 13:45:48 Источник Nasdaq GlobeNewswire

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

28 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Participate in the BIO International Convention

21 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

15 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

14 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

13 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

09 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

15 апр 2024 05:30:00 Источник Nasdaq GlobeNewswire

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

15 апр 2024 05:05:00 Источник Nasdaq GlobeNewswire